Pay in 4 interest-free payments of $6.15 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
Triple Agonists (GLP-1/GIP/Glucagon) Titration and Tapering Algorithms At a glance Prototype agent / retatrutide (LY3437943), subcutaneous weekly injection Phase 2 peak weight loss / 24.2% at 48 weeks (12 mg cohort, N=338 total trial) Titration duration / 24 weeks across 4 dose steps before reaching maintenance Starting dose / 2 mg subcutaneous once weekly for weeks 1 to 4 Maintenance dose range / 8 mg or 12 mg once weekly depending on tolerability Primary targets / obesity, MASLD, type 2 diabetes, metabolic syndrome GI adverse events / nausea in 53 to 65% of participants at higher dose steps Taper recommendation / dose reduction over 8 to 12 weeks when discontinuing FDA status / Phase 3 (TRIUMPH program) ongoing as of early 2025
In a rat model of autoimmune thyroiditis, TGPL significantly lowered serum TPOAb, TGAb, and TNF- levels while boosting IL-10 levels and ameliorating thyroid follicle damage
Magnesium is an essential mineral for the body, and it is involved in many aspects of health
AXA S.A
Data extraction The data extracted from each study included information on the first author, publication year, country, criteria for inclusion and exclusion, follow-up duration, baseline characteristics of participants, drug history, lab data, treatment characteristics, and outcomes
